Table 1

Summary of patient demographics and concomitant therapy

CBD (n = 13)THCV (n = 12)1:1 CBD/THCV (n = 11)20:1 CBD/THCV (n = 12)Placebo (n = 14)Total (n = 62)
Male, number of subjects (%)10 (77)10 (83)6 (55)9 (75)7 (50)42 (68)
Female, number of subjects (%)3 (23)2 (17)5 (45)3 (25)7 (50)20 (32)
Age (years), mean (SD)56.8 (9.9)62.5 (12.6)59.3 (8.8)58.0 (8.1)58.6 (7.7)59.0 (9.4)
Weight (kg), mean (SD)97.2 (13.8)98.3 (17.5)100.7 (14.5)100.5 (17.9)94.2 (19.1)98.0 (16.4)
BMI (kg/m2), mean (SD)33.2 (5.4)34.0 (6.5)36.4 (5.6)35.4 (4.6)33.4 (7.0)34.4 (5.8)
Duration since diagnosis of diabetes (years), mean (SD)2.8 (3.3)4.8 (3.6)4.4 (2.7)5.1 (3.3)3.8 (3.5)4.2 (3.3)
Number (%) of patients on antidiabetic and lipid-lowering therapy
 Metformin9 (69)9 (75)10 (91)11 (92)12 (86)51 (82)
 DPP-4 inhibitors1 (8)1 (8)1 (9)1 (8)1 (7)5 (8)
 Sulfonylureas3 (23)5 (42)4 (36)3 (25)4 (29)19 (31)
 Statins9 (69)11 (92)10 (91)8 (67)13 (93)51 (82)
  • DPP-4, dipeptidyl peptidase 4.